ACADIA PHARMACEUTICALS INC. - 10-Q Summary (Q3 2024)
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on central nervous system (CNS) disorders and rare diseases. Its commercial portfolio consists of NUPLAZID (pimavanserin) for Parkinson's disease psychosis and DAYBUE (trofinetide) for Rett syndrome. In October 2024, Health Canada granted marketing authorization for DAYBUE.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenues | $250,401 | $211,699 | $698,195 | $495,396 |
| Net Income (Loss) | $32,765 | $(65,176) | $82,709 | $(107,083) |
| Diluted EPS | $0.20 | $(0.40) | $0.50 | $(0.65) |
| Operating Cash Flow (9M) | $117,338 | $(68,687) | $117,338 | $(68,687) |
| Cash & Investments (Total) | $565,330 | $438,865 | $565,330 | $438,865 |
| Accumulated Deficit | $(2,348,128) | $(2,476,634) | $(2,348,128) | $(2,476,634) |
Note: Cash & Investments calculated as Cash ($155,149) + Investment Securities ($410,181).
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 18% in Q3 2024 compared to Q3 2023, driven by growth in both NUPLAZID ($159.2M vs $144.8M) and DAYBUE ($91.2M vs $66.9M). DAYBUE sales growth was significant, with 9M 2024 sales reaching $251.7M compared to $90.1M in 9M 2023.
- Profitability Turnaround: The company reported a net income of $32.8M in Q3 2024, a reversal from a net loss of $65.2M in the same period last year. This was driven by revenue growth and a significant decrease in R&D expenses.
- Expense Fluctuations:
- R&D Expenses: Decreased to $66.6M in Q3 2024 from $157.0M in Q3 2023. The decline is primarily due to the absence of a $100M upfront payment to Neuren Pharmaceuticals made in Q3 2023 for an expanded license agreement.
- SG&A Expenses: Increased to $133.3M in Q3 2024 from $97.9M in Q3 2023. This increase was driven by consumer activation programs for NUPLAZID and approximately $14.9M in transition costs related to the departure of the former CEO and appointment of the new CEO.
- Inventory Build-up: Total inventory increased to $86.7M (including long-term) from $40.4M at year-end 2023, reflecting strategic stockpiling of raw materials.
Guidance, Outlook, and Risks
- Outlook: Management expects cash, cash equivalents, and investment securities to be sufficient to fund operations through and beyond the next 12 months. The company anticipates continued substantial R&D expenses for pipeline programs (ACP-101, ACP-204) and post-marketing requirements for DAYBUE.
- Subsequent Event: In November 2024, the company entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150.0 million. One-third of the net proceeds will be payable to Neuren Pharmaceuticals.
- Risks and Contingencies:
- Legal Proceedings: Ongoing patent infringement litigation regarding NUPLAZID (Pimavanserin I and II cases) against MSN Laboratories and Aurobindo. A securities class action and a derivative suit are also pending, though the derivative suit is currently stayed.
- Regulatory: DAYBUE is subject to post-marketing requirements (PMRs). The company has completed one PMR and is awaiting FDA acceptance of another.
- Commercial: Success depends on market acceptance of DAYBUE for Rett syndrome and maintaining NUPLAZID sales. The company faces competition from off-label antipsychotics for PDP and potential gene therapies for Rett syndrome.
Key Investor Verification Points
- DAYBUE Royalty Obligations: Verify the impact of the $50.0 million milestone payment due to Neuren (triggered by exceeding $250M in North American net sales) and the tiered royalty structure (10-12%) on future margins.
- CEO Transition Costs: Confirm the one-time nature of the ~$15M SG&A increase related to the CEO transition and assess the long-term impact of the new leadership strategy.
- PRV Sale Closing: Monitor the closing of the $150M PRV sale and the subsequent cash inflow, noting the 1/3 share payable to Neuren.
- Patent Litigation Status: Track the outcome of the appeal in the Pimavanserin I case (MSN) and the upcoming trial in the Pimavanserin II case, as these directly impact the exclusivity period for NUPLAZID.
- Inventory Valuation: Review the significant increase in inventory ($46M increase) to ensure it aligns with commercial demand forecasts and does not indicate obsolescence risk.